interleukin-2

aldesleukin (interleukin-2, IL-2)

Proleukin

Pharmacologic class: Interleukin-2 (IL-2), human recombinant (cytokine)

Therapeutic class: Antineoplastic (miscellaneous)

Pregnancy risk category C

FDA Box Warning

• Give only to patients with normal cardiac and pulmonary function, as shown by thallium stress testing and pulmonary function testing. Use extreme caution when giving to patients with normal thallium stress test and normal pulmonary function tests who have a history of cardiac or pulmonary disease.

• Give under supervision of physician experienced in cancer chemotherapy, in setting where intensive care facilities and cardiopulmonary or intensive care specialists are available.

• Drug is linked to capillary leak syndrome, which causes hypotension and reduced organ perfusion (possibly severe and resulting in death).

• Before starting drug, preexisting bacterial infections must be treated, because drug may impair neutrophil function and increase disseminated infection risk. Patients with indwelling central lines are at special risk for infection with gram-positive microorganisms. Prophylactic antibiotics can help prevent staphylococcal infections.

• Withhold drug in patients who develop moderate to severe lethargy or somnolence; continued administration may cause coma.

Action

Activates cellular immunity and inhibits tumor growth by increasing lymphocytes and cytokines, which lyse tumor cells

Availability

Injection: 22 million international units/vial

Indications and dosages

➣ Metastatic renal cell carcinoma and metastatic melanoma

Adults older than age 18: 600,000 international units/kg I.V. given over 15 minutes q 8 hours for a maximum of 14 doses, followed by 9 days of rest. Repeat for another 14 doses, for a maximum of 28 doses per course.

Off-label uses

• Colorectal cancer

• Kaposi's sarcoma

• Non-Hodgkin's lymphoma

Contraindications

• Hypersensitivity to drug

• Arrhythmias, cardiac tamponade, seizures, severe GI bleeding, coma or toxic psychosis lasting more than 48 hours

• Organ allograft

• Abnormal thallium stress test or pulmonary function test results

Precautions

Use cautiously in:

• anemia, bacterial infections, heart disease, CNS metastases, hepatic disease, pulmonary disease, renal disease, thrombocytopenia

• pregnant or breastfeeding patients

• children.

Administration

• Make sure patient's thallium stress test and pulmonary function test results are normal before giving.

See Don't give if patient is drowsy or severely lethargic; contact prescriber immediately.

• Reconstitute drug according to label directions with 1.2 ml of sterile water for injection by injecting diluent against side of vial (to prevent excessive foaming).

• Further dilute reconstituted dose with 50 ml of 5% dextrose injection.

• Administer I.V. infusion over 15 minutes.

• Don't use in-line filter.

Adverse reactions

CNS: dizziness, mental status changes, syncope, sensory or motor dysfunction, headache, fatigue, rigors, weakness, malaise, poor memory, depression, sleep disturbances, hallucinations

CV: bradycardia, sinus tachycardia, premature atrial complexes, premature ventricular contractions, arrhythmias, myocardial ischemia, cardiac arrest, capillary leak syndrome and severe hypotension, myocardial infarction EENT: reversible vision changes, conjunctivitis

GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, stomatitis, anorexia, intestinal perforation, ileus, GI bleeding

GU: hematuria, proteinuria, dysuria, renal failure, oliguria or anuria Hematologic: anemia, purpura, eosinophilia, thrombocytopenia, coagulation disorders, leukopenia, leukocytosis

Hepatic: jaundice, ascites

Metabolic: hyperglycemia, hypoglycemia, acidosis, alkalosis

Musculoskeletal: joint and back pain, myalgia

Respiratory: cough, chest pain, tachypnea, wheezing, dyspnea, pulmonary congestion, pulmonary edema, respiratory failure, apnea, pleural effusion

Skin: erythema, pruritus, rash, dry skin, petechiae, urticaria, exfoliative dermatitis

Other: weight gain or loss, fever, chills, edema, infection, pain or reaction at injection site, hypersensitivity reaction

Interactions

Drug-drug. Aminoglycosides, asparaginase, cytotoxic chemotherapy agents, doxorubicin, indomethacin, methotrexate: increased toxicity

Antihypertensives: increased hypotensive effect

Glucocorticoids: reduced antitumor effects

Drug-diagnostic tests. Alkaline phosphatase, bilirubin, glucose, blood urea nitrogen, creatinine, potassium, transaminases: increased levels

Calcium, glucose, magnesium, phosphorus, potassium, protein sodium, uric acid: decreased levels

Patient monitoring

• Monitor heart rate and rhythm, vital signs, and fluid intake and output.

• Assess for signs and symptoms of hypersensitivity reaction and infection.

• Monitor for adverse CNS effects. Report these immediately.

• Evaluate chest X-rays.

• Monitor CBC, electrolyte levels, and liver and kidney function test results.

Patient teaching

See Tell patient that drug lowers resistance to infections. Advise him to immediately report fever, cough, breathing problems, and other signs or symptoms of infection.

See Advise patient to immediately report chest pain, irregular or fast heart beats, easy bruising or bleeding, or abdominal pain.

• Instruct patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

• Provide dietary counseling. Refer patient to dietitian if adverse GI effects significantly limit food intake.

• Notify patient that he'll undergo blood testing and have chest X-rays taken during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

in·ter·leu·kin-·2

(in'tĕr-lū'kin), A cytokine derived from T-helper lymphocytes that causes proliferation of T lymphocytes and activated B lymphocytes; maintains long-term culturs of T cells.

interleukin-2

(ĭn′tər-lo͞o′kĭn-to͞o′)n. A cytokine that is released by T cells in response to an antigen and that regulates the growth and differentiation of B cells, monocytes, and many types of T cells. It has been used experimentally to treat cancer.

IL2

A gene on chromosome 4q26-q27 that encodes interleukin-2, a cytokine secreted by T cells in response to antigenic or mitogenic stimulation that plays a central role in the proliferation of T and B lymphocytes. IL-2 upregulates B-cells, monocytes, lymphokine-activated killer cells, natural killer cells and glioma cells.

in·ter·leu·kin-2

(in'tĕr-lū'kin) A cytokine derived from T-helper lymphocytes that causes proliferation of T lymphocytes and activated B lymphocytes.

interleukin-2

A peptide chemical mediator released by helper T LYMPHOCYTES that stimulates clonal T cell and B cell division and proliferation. It is known as the T cell growth factor and is responsible for the activation on natural killer T cells.

in·ter·leu·kin-2

(in'tĕr-lū'kin) A cytokine derived from T-helper lymphocytes that causes proliferation of T lymphocytes and activated B lymphocytes.

单词	interleukin-2
释义	interleukin-2 in·ter·leu·kin-2 I0189150 (ĭn′tər-lo͞o′kĭn-to͞o′)n. A cytokine that is released by T cells in response to an antigen and regulates the proliferation and differentiation of natural killer cells, B cells, and other T cells. It has been used experimentally to treat cancer. interleukin-2 interleukin-2 [‚in·tər¦lük·ən ′tü] (immunology) A lymphokine secreted mostly by helper T lymphocytes that promotes the growth of T lymphocytes. Abbreviated IL-2. interleukin-2 aldesleukin (interleukin-2, IL-2) Proleukin *Pharmacologic class:* Interleukin-2 (IL-2), human recombinant (cytokine) *Therapeutic class:* Antineoplastic (miscellaneous) *Pregnancy risk category C* FDA Box Warning • Give only to patients with normal cardiac and pulmonary function, as shown by thallium stress testing and pulmonary function testing. Use extreme caution when giving to patients with normal thallium stress test and normal pulmonary function tests who have a history of cardiac or pulmonary disease. • Give under supervision of physician experienced in cancer chemotherapy, in setting where intensive care facilities and cardiopulmonary or intensive care specialists are available. • Drug is linked to capillary leak syndrome, which causes hypotension and reduced organ perfusion (possibly severe and resulting in death). • Before starting drug, preexisting bacterial infections must be treated, because drug may impair neutrophil function and increase disseminated infection risk. Patients with indwelling central lines are at special risk for infection with gram-positive microorganisms. Prophylactic antibiotics can help prevent staphylococcal infections. • Withhold drug in patients who develop moderate to severe lethargy or somnolence; continued administration may cause coma. Action Activates cellular immunity and inhibits tumor growth by increasing lymphocytes and cytokines, which lyse tumor cells Availability Injection: 22 million international units/vial Indications and dosages ➣ Metastatic renal cell carcinoma and metastatic melanoma Adults older than age 18: 600,000 international units/kg I.V. given over 15 minutes q 8 hours for a maximum of 14 doses, followed by 9 days of rest. Repeat for another 14 doses, for a maximum of 28 doses per course. Off-label uses • Colorectal cancer • Kaposi's sarcoma • Non-Hodgkin's lymphoma Contraindications • Hypersensitivity to drug • Arrhythmias, cardiac tamponade, seizures, severe GI bleeding, coma or toxic psychosis lasting more than 48 hours • Organ allograft • Abnormal thallium stress test or pulmonary function test results Precautions Use cautiously in: • anemia, bacterial infections, heart disease, CNS metastases, hepatic disease, pulmonary disease, renal disease, thrombocytopenia • pregnant or breastfeeding patients • children. Administration • Make sure patient's thallium stress test and pulmonary function test results are normal before giving. See Don't give if patient is drowsy or severely lethargic; contact prescriber immediately. • Reconstitute drug according to label directions with 1.2 ml of sterile water for injection by injecting diluent against side of vial (to prevent excessive foaming). • Further dilute reconstituted dose with 50 ml of 5% dextrose injection. • Administer I.V. infusion over 15 minutes. • Don't use in-line filter. Adverse reactions CNS: dizziness, mental status changes, syncope, sensory or motor dysfunction, headache, fatigue, rigors, weakness, malaise, poor memory, depression, sleep disturbances, hallucinations CV: bradycardia, sinus tachycardia, premature atrial complexes, premature ventricular contractions, arrhythmias, myocardial ischemia, cardiac arrest, capillary leak syndrome and severe hypotension, myocardial infarction EENT: reversible vision changes, conjunctivitis GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, stomatitis, anorexia, intestinal perforation, ileus, GI bleeding GU: hematuria, proteinuria, dysuria, renal failure, oliguria or anuria Hematologic: anemia, purpura, eosinophilia, thrombocytopenia, coagulation disorders, leukopenia, leukocytosis Hepatic: jaundice, ascites Metabolic: hyperglycemia, hypoglycemia, acidosis, alkalosis Musculoskeletal: joint and back pain, myalgia Respiratory: cough, chest pain, tachypnea, wheezing, dyspnea, pulmonary congestion, pulmonary edema, respiratory failure, apnea, pleural effusion Skin: erythema, pruritus, rash, dry skin, petechiae, urticaria, exfoliative dermatitis Other: weight gain or loss, fever, chills, edema, infection, pain or reaction at injection site, hypersensitivity reaction Interactions Drug-drug. Aminoglycosides, asparaginase, cytotoxic chemotherapy agents, doxorubicin, indomethacin, methotrexate: increased toxicity Antihypertensives: increased hypotensive effect Glucocorticoids: reduced antitumor effects Drug-diagnostic tests. Alkaline phosphatase, bilirubin, glucose, blood urea nitrogen, creatinine, potassium, transaminases: increased levels Calcium, glucose, magnesium, phosphorus, potassium, protein sodium, uric acid: decreased levels Patient monitoring • Monitor heart rate and rhythm, vital signs, and fluid intake and output. • Assess for signs and symptoms of hypersensitivity reaction and infection. • Monitor for adverse CNS effects. Report these immediately. • Evaluate chest X-rays. • Monitor CBC, electrolyte levels, and liver and kidney function test results. Patient teaching See Tell patient that drug lowers resistance to infections. Advise him to immediately report fever, cough, breathing problems, and other signs or symptoms of infection. See Advise patient to immediately report chest pain, irregular or fast heart beats, easy bruising or bleeding, or abdominal pain. • Instruct patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids. • Provide dietary counseling. Refer patient to dietitian if adverse GI effects significantly limit food intake. • Notify patient that he'll undergo blood testing and have chest X-rays taken during therapy. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above. in·ter·leu·kin-·2 (in'tĕr-lū'kin), A cytokine derived from T-helper lymphocytes that causes proliferation of T lymphocytes and activated B lymphocytes; maintains long-term culturs of T cells. interleukin-2 (ĭn′tər-lo͞o′kĭn-to͞o′)n. A cytokine that is released by T cells in response to an antigen and that regulates the growth and differentiation of B cells, monocytes, and many types of T cells. It has been used experimentally to treat cancer. IL2 A gene on chromosome 4q26-q27 that encodes interleukin-2, a cytokine secreted by T cells in response to antigenic or mitogenic stimulation that plays a central role in the proliferation of T and B lymphocytes. IL-2 upregulates B-cells, monocytes, lymphokine-activated killer cells, natural killer cells and glioma cells. in·ter·leu·kin-2 (in'tĕr-lū'kin) A cytokine derived from T-helper lymphocytes that causes proliferation of T lymphocytes and activated B lymphocytes. interleukin-2 A peptide chemical mediator released by helper T LYMPHOCYTES that stimulates clonal T cell and B cell division and proliferation. It is known as the T cell growth factor and is responsible for the activation on natural killer T cells. in·ter·leu·kin-2 (in'tĕr-lū'kin) A cytokine derived from T-helper lymphocytes that causes proliferation of T lymphocytes and activated B lymphocytes. AcronymsSeeIL2ThesaurusSeeinterleukin
随便看	emergency malfunction and display system emergency malpractice liability insurance commission emergency management emergency management academy of new zealand emergency management accreditation program emergency management administration emergency management advisory coalition emergency management agency emergency management alliance of indiana emergency management and continuity planning emergency management and homeland security division emergency management and national preparedness program emergency management and research institute emergency management and response emergency management and response-information sharing and analysis center emergency management association of tennessee emergency management australia emergency management command and coordination emergency management coordinator emergency management exercise emergency management hazards assessment emergency management hazards survey emergency management institute emergency management issues emergency management of severe trauma